Clinical trials: Advanced Malignant Solid Tumors
Advanced Solid Tumors
A Study of Docetaxel Polymeric Micelles for Injection in Patients With Advanced Solid Tumors
This study is an open, multi-cohort phase II clinical trial, the overall design is divided into two parts: dose confirmation stage and expansion stage.
- Trial name
- NCT05254665
- Testing
- Docetaxel Polymeric Micelles for Injection
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Solid Tumor, Advanced Solid Tumor
A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy…
- Conditions
- Solid Tumor, Advanced Solid Tumor, Non Small Cell Lung Cancer, Colo-rectal Cancer
- Trial name
- NCT05578092
- Testing
- MRTX0902, MRTX849
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Mirati Therapeutics Inc.
Mesothelioma, Non Small Cell Lung Cancer
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the…
- Conditions
- Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor
- Trial name
- NCT05245500
- Testing
- MRTX1719
- Where
- 25 sites in United States
- Volunteers
- 336 people
- Sponsor
- Bristol-Myers Squibb
Advanced Malignant Tumour
A Phase I Clinical Study of HRS-7058 in Patients With Advanced Malignant Tumour
This study is a multicentre, open phase I clinical study of dose escalation, dose extension and efficacy extension of HRS-7058 in subjects with advanced malignant tumour.
- Trial name
- NCT06383871
- Testing
- HRS-7058 capsule/ HRS-7058 tablet
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Advanced Malignant Solid Tumor
A Study of MHB118C Injection in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I study of MHB118C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT07045454
- Testing
- MHB118C for Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Malignant Neoplasms, Metastatic Cancer
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Evaluate the safety and tolerability of BPI-421286 in adult subjects with advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with advanced solid tumors.
- Trial name
- NCT05315180
- Testing
- BPI-421286
- Where
- 5 sites in China
- Volunteers
- 80 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Advanced/Metastatic Solid Tumors
Study of MHB088C for Patients With Advanced Solid Malignant Tumors
This is a Phase I/II, multicenter, open-label clinical trial with dose escalation/dose expansion/efficacy expansion phases, designed to evaluate the safety/tolerability, pharmacokinetics, immunogenicity and preliminary efficacy…
- Trial name
- NCT07102004
- Testing
- MHB088C for Injection
- Where
- China
- Volunteers
- 515 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors.
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced
- Trial name
- NCT03212404
- Testing
- CK-301 (cosibelimab)
- Where
- 48 sites in Australia, France and 7 more
- Volunteers
- 272 people
- Sponsor
- Checkpoint Therapeutics, Inc.
Solid Tumor, Adult
A Phase l Study of By101298, an Oral DNA-PK Inhibitor, in Patients With Advanced Solid Tumors
BY101298 is an innovative DNA-dependent protein kinases (DNA-PK) highly selective small molecule inhibitor. DNA-dependent protein kinases (DNA-PK plays a key role in the NHEJ repair pathway to repair DNA double-strand breaks…
- Trial name
- NCT06462716
- Testing
- BY101298 Capsules
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chengdu Baiyu Pharmaceutical Co., Ltd.
Solid Tumor
A Phase I /IIa Study of RC88-ADC in Subjects With Advanced Malignant Solid Tumors
This was a multicenter, open, multi-cohort extended PHASE I/IIa study, consisting of 2 phases:Phase I (Phase I dose escalation) and Phase II (Phase IIa multi-cohort extension).
- Trial name
- NCT04175847
- Testing
- RC88
- Where
- 4 sites in China
- Volunteers
- 198 people
- Sponsor
- RemeGen Co., Ltd.
Advanced Malignant Solid Neoplasm, RAS Mutation
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed…
- Conditions
- Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer, Colon Cancer
- Trial name
- NCT04678648
- Testing
- RSC-1255 Dose Escalation, RSC-1255 Dose Expansion
- Where
- 3 sites in United States
- Volunteers
- 134 people
- Sponsor
- RasCal Therapeutics, Inc.
Malignant Mesothelioma, Colorectal Cancer
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
This is a first-in-human, single-arm, open-label, dose escalation clinical study to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic characteristics, immunogenicity and preliminary efficacy of UCMYM802…
- Conditions
- Malignant Mesothelioma, Colorectal Cancer, Bile Duct Cancer, Rectal Cancer
- Trial name
- NCT06256055
- Testing
- UCMYM802 Injection
- Where
- China
- Volunteers
- 24 people
- Sponsor
- UTC Therapeutics Inc.
Solid Tumor
A Study of RC108-ADC in Subjects With Advanced Malignant Solid Tumors
This study will evaluate the safety, pharmacokinetics, and effect of RC108-ADC for injeciton in subjects with c-Met positive advanced malignant solid tumors.
- Trial name
- NCT04617314
- Testing
- RC108
- Where
- 4 sites in China
- Volunteers
- 67 people
- Sponsor
- RemeGen Co., Ltd.
Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor…
- Conditions
- Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma, P53 Mutation
- Trial name
- NCT03611868
- Testing
- Phase 1b: APG-115+pembrolizumab
- Where
- 21 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- Ascentage Pharma Group Inc.
Neoplasms Malignant
A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK112, a PD-1/VEGF bispecific antibody, as a single agent in adult subjects with…
- Trial name
- NCT04047290
- Testing
- AK112
- Where
- 7 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Akesobio Australia Pty Ltd
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
An Open-label Study of SG1827 Combined With Anti-PD-1/PD-L1 Antibody and Bevacizumab in Patients With Advanced Solid Tumors
This multicenter, open-label Phase Ib/II study with dose escalation and expansion in Chinese patients with advanced solid tumors consists of Part A (SG1827 plus anti-PD-1/PD-L1) and Part B (SG1827 plus anti-PD-1/PD-L1 and…
- Trial name
- NCT07774611
- Testing
- SG1827, anti-PD-1/PD-L1 antibody, bevacizumab
- Where
- 10 sites in China
- Volunteers
- 180 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Advanced Solid Tumor, Advanced Breast Cancer
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in…
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
- Trial name
- NCT06120283
- Testing
- BGB-43395, Fulvestrant, Letrozole
- Where
- 61 sites in United States, Australia and 9 more
- Volunteers
- 433 people
- Sponsor
- BeOne Medicines
Advanced Malignant Solid Tumors
A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors
This is a phase I clinical study to evaluate safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Axl inhibitor FC084CSA in patients with advanced malignant solid tumors who have failed standard…
- Trial name
- NCT06231550
- Testing
- FC084CSA tablets
- Where
- China
- Volunteers
- 21 people
- Sponsor
- FindCure Biosciences (ZhongShan) Co., Ltd.
Malignant Solid Tumors
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
This is an open-label, multi-center phase 1b study to evaluate the safety and efficacy of Sirolimus for injection (albumin-bound) in patients with malignant solid tumors with TSC1 or TSC2 genetic alterations.
- Trial name
- NCT05508620
- Testing
- Sirolimus for Injection (Albumin-bound)
- Volunteers
- 270 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.